Gastric Cancer | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Gastric Cancer

A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)

Sub-indication: Gastrointestinal Cancer

Study Type: Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Seattle Genetics, Inc

Learn more at ClinicalTrials.gov

Email for more information: GI-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Gastric Cancer Clinical Trial

Schedule an Appointment